Research ExplorerPublicationsUnmanipulated haploidentical in comparison with matched unre...

Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT

Standard

Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. / Santoro, Nicole; Labopin, Myriam; Giannotti, Federica; Ehninger, Gerard; Niederwieser, Dietger; Brecht, Arne; Stelljes, Matthias; Kröger, Nicolaus; Einsele, Herman; Eder, Matthias; Hallek, Michael; Glass, Bertram; Finke, Jürgen; Ciceri, Fabio; Mohty, Mohamad; Ruggeri, Annalisa; Nagler, Arnon.

In: J HEMATOL ONCOL, Vol. 11, No. 1, 16.04.2018, p. 55.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Santoro, N, Labopin, M, Giannotti, F, Ehninger, G, Niederwieser, D, Brecht, A, Stelljes, M, Kröger, N, Einsele, H, Eder, M, Hallek, M, Glass, B, Finke, J, Ciceri, F, Mohty, M, Ruggeri, A & Nagler, A 2018, 'Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT', J HEMATOL ONCOL, vol. 11, no. 1, pp. 55. https://doi.org/10.1186/s13045-018-0598-0

APA

Santoro, N., Labopin, M., Giannotti, F., Ehninger, G., Niederwieser, D., Brecht, A., Stelljes, M., Kröger, N., Einsele, H., Eder, M., Hallek, M., Glass, B., Finke, J., Ciceri, F., Mohty, M., Ruggeri, A., & Nagler, A. (2018). Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. J HEMATOL ONCOL, 11(1), 55. https://doi.org/10.1186/s13045-018-0598-0

Vancouver

Santoro N, Labopin M, Giannotti F, Ehninger G, Niederwieser D, Brecht A et al. Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. J HEMATOL ONCOL. 2018 Apr 16;11(1):55. https://doi.org/10.1186/s13045-018-0598-0

Bibtex

@article{b4c722c8a5ea4785bda3049d50ba8fa3,
title = "Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT",
abstract = "BACKGROUND: Acute myeloid leukemia (AML) is both more common and with more biologically aggressive phenotype in the elderly. Allogenic stem cell transplantation (allo-SCT) is the best treatment option in fit patients. Either HLA-matched unrelated donor (MUD) or haploidentical (Haplo) donor are possible alternative for patients in need.METHODS: We retrospectively compared non-T-cell-depleted Haplo (n = 250) to 10/10 MUD (n = 2589) in AML patients ≥ 60 years.RESULTS: Median follow-up was 23 months. Disease status at transplant differs significantly between the two groups (p < 10-4). Reduced intensity conditioning (RIC) was administrated to 73 and 77% of Haplo and MUD, respectively (p = 0.23). Stem cell source was the bone marrow (BM) in 52% of the Haplo and 6% of MUD (p < 10-4). Anti-thymocyte globulin (ATG) was most frequently used in MUD (p < 10-4) while post-Tx cyclophosphamide (PT-Cy) was given in 62% of Haplo. Engraftment was achieved in 90% of the Haplo vs 97% of MUD (p < 10-4). In multivariate analysis, no significant difference was found between Haplo and MUD for acute (a)graft versus host disease (GVHD) grade II-IV, relapse incidence (RI), non-relapse mortality (NRM), leukemia free survival (LFS), graft-versus-host-free-relapse free survival (GRFS), and overall survival (OS). Extensive chronic (c)GVHD was significantly higher for MUD as compared to Haplo (HR 2, p = 0.01, 95% CI 1.17-3.47). A propensity score analysis confirmed the higher risk of extensive cGVHD for MUD without differences for other outcomes.CONCLUSIONS: Allo-SCT from both Haplo and MUD are valid option for AML patients ≥ 60 years of age with similar results. Transplantation from MUD was associated with higher extensive cGVHD. Our findings suggest that Haplo is a suitable and attractive graft source for patients≥ 60 with AML in need of allo-SCT.",
keywords = "Journal Article",
author = "Nicole Santoro and Myriam Labopin and Federica Giannotti and Gerard Ehninger and Dietger Niederwieser and Arne Brecht and Matthias Stelljes and Nicolaus Kr{\"o}ger and Herman Einsele and Matthias Eder and Michael Hallek and Bertram Glass and J{\"u}rgen Finke and Fabio Ciceri and Mohamad Mohty and Annalisa Ruggeri and Arnon Nagler",
year = "2018",
month = apr,
day = "16",
doi = "10.1186/s13045-018-0598-0",
language = "English",
volume = "11",
pages = "55",
journal = "J HEMATOL ONCOL",
issn = "1756-8722",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT

AU - Santoro, Nicole

AU - Labopin, Myriam

AU - Giannotti, Federica

AU - Ehninger, Gerard

AU - Niederwieser, Dietger

AU - Brecht, Arne

AU - Stelljes, Matthias

AU - Kröger, Nicolaus

AU - Einsele, Herman

AU - Eder, Matthias

AU - Hallek, Michael

AU - Glass, Bertram

AU - Finke, Jürgen

AU - Ciceri, Fabio

AU - Mohty, Mohamad

AU - Ruggeri, Annalisa

AU - Nagler, Arnon

PY - 2018/4/16

Y1 - 2018/4/16

N2 - BACKGROUND: Acute myeloid leukemia (AML) is both more common and with more biologically aggressive phenotype in the elderly. Allogenic stem cell transplantation (allo-SCT) is the best treatment option in fit patients. Either HLA-matched unrelated donor (MUD) or haploidentical (Haplo) donor are possible alternative for patients in need.METHODS: We retrospectively compared non-T-cell-depleted Haplo (n = 250) to 10/10 MUD (n = 2589) in AML patients ≥ 60 years.RESULTS: Median follow-up was 23 months. Disease status at transplant differs significantly between the two groups (p < 10-4). Reduced intensity conditioning (RIC) was administrated to 73 and 77% of Haplo and MUD, respectively (p = 0.23). Stem cell source was the bone marrow (BM) in 52% of the Haplo and 6% of MUD (p < 10-4). Anti-thymocyte globulin (ATG) was most frequently used in MUD (p < 10-4) while post-Tx cyclophosphamide (PT-Cy) was given in 62% of Haplo. Engraftment was achieved in 90% of the Haplo vs 97% of MUD (p < 10-4). In multivariate analysis, no significant difference was found between Haplo and MUD for acute (a)graft versus host disease (GVHD) grade II-IV, relapse incidence (RI), non-relapse mortality (NRM), leukemia free survival (LFS), graft-versus-host-free-relapse free survival (GRFS), and overall survival (OS). Extensive chronic (c)GVHD was significantly higher for MUD as compared to Haplo (HR 2, p = 0.01, 95% CI 1.17-3.47). A propensity score analysis confirmed the higher risk of extensive cGVHD for MUD without differences for other outcomes.CONCLUSIONS: Allo-SCT from both Haplo and MUD are valid option for AML patients ≥ 60 years of age with similar results. Transplantation from MUD was associated with higher extensive cGVHD. Our findings suggest that Haplo is a suitable and attractive graft source for patients≥ 60 with AML in need of allo-SCT.

AB - BACKGROUND: Acute myeloid leukemia (AML) is both more common and with more biologically aggressive phenotype in the elderly. Allogenic stem cell transplantation (allo-SCT) is the best treatment option in fit patients. Either HLA-matched unrelated donor (MUD) or haploidentical (Haplo) donor are possible alternative for patients in need.METHODS: We retrospectively compared non-T-cell-depleted Haplo (n = 250) to 10/10 MUD (n = 2589) in AML patients ≥ 60 years.RESULTS: Median follow-up was 23 months. Disease status at transplant differs significantly between the two groups (p < 10-4). Reduced intensity conditioning (RIC) was administrated to 73 and 77% of Haplo and MUD, respectively (p = 0.23). Stem cell source was the bone marrow (BM) in 52% of the Haplo and 6% of MUD (p < 10-4). Anti-thymocyte globulin (ATG) was most frequently used in MUD (p < 10-4) while post-Tx cyclophosphamide (PT-Cy) was given in 62% of Haplo. Engraftment was achieved in 90% of the Haplo vs 97% of MUD (p < 10-4). In multivariate analysis, no significant difference was found between Haplo and MUD for acute (a)graft versus host disease (GVHD) grade II-IV, relapse incidence (RI), non-relapse mortality (NRM), leukemia free survival (LFS), graft-versus-host-free-relapse free survival (GRFS), and overall survival (OS). Extensive chronic (c)GVHD was significantly higher for MUD as compared to Haplo (HR 2, p = 0.01, 95% CI 1.17-3.47). A propensity score analysis confirmed the higher risk of extensive cGVHD for MUD without differences for other outcomes.CONCLUSIONS: Allo-SCT from both Haplo and MUD are valid option for AML patients ≥ 60 years of age with similar results. Transplantation from MUD was associated with higher extensive cGVHD. Our findings suggest that Haplo is a suitable and attractive graft source for patients≥ 60 with AML in need of allo-SCT.

KW - Journal Article

U2 - 10.1186/s13045-018-0598-0

DO - 10.1186/s13045-018-0598-0

M3 - SCORING: Journal article

C2 - 29661208

VL - 11

SP - 55

JO - J HEMATOL ONCOL

JF - J HEMATOL ONCOL

SN - 1756-8722

IS - 1

ER -